Allergan, Inc.

Amgen Inc.

Anuradha V Gore

Chetan Pujara

John T Trogden

Robert S Jordan

Ke Wu

Michael R Robinson

Rhett M Schiffman

Chin-Ming Chang

Richard S Graham

Kevin S Warner

Mohammed I Dibas

R Scott Jordan

Jaya Giyanani

Adnan K Salameh

Kevin Krock

Chetan P Pujara

Sukhon Likitlersuang

Prem Swaroop Mohanty

E Quinn Farnes

Sesha Neervannan

Scott W Smith

Mayssa Attar

Sai Shankar

Aileen Morgan

Andrea S Kim

Ajay P Parashar

Jie Shen

Jihao Zhou

Ronald Bradford

Sungwook Lee

Haixia Liu

Thomas K Karami

Kristin B Prinn

Seshadri Neervannan

Mu-Lan Lee

Kiomars Karami

Roger Zanon

Christopher W Spancake

Anne Navratil

Ramakrishnan Srikumar

Melissa Gulmezian

Hao Hou

Kristin Prinn

Mohammed Dibas

Jim Jiao

Described herein are methods and compositions for the treatment of ocular conditions and for the improvement of vision parameters using pharmaceutically acceptable ophthalmic pilocarpine formulations. A nonlimiting example of an ocular condition that may be treated with the methods and compositions disclosed herein is presbyopia.

Presbyopia treatments

The present invention provides ophthalmic compositions, e.g. artificial tears, suitable for treating dry eye syndrome in a human or other mammal suffering there from, e.g. a dog or cat, which comprise a mixture of castor oil with another oil, e.g. a food oil, e.g. olive oil, sesame oil, corn oil etc.

Artificial tears and therapeutic uses

The disclosure provides compositions for treating an ocular condition. The composition comprises a physiologically effective amount of an androgen, wherein the composition is suitable for topical administration to an eye. The disclosure further provides methods for treating an ocular condition with the disclosed compositions.

Androgen composition for treating an ophthalmic condition

Disclosed herein are emulsions comprising testosterone or related androgens, castor oil, cyclodextrin, Pemulen TR-2, Polyoxyl 40, and other ingredients. The compositions are useful for treating keratoconjunctivitis sicca and meibomian gland disease.

Non-irritating testosterone emulsions

The present disclosure relates to suspension formulations and systems for the treatment of ocular conditions. The suspension formulations can include cyclosporin A and in some embodiments, Form 1 or Form 2 cyclosporin A. A delivery system can be provided that includes two parts, a first part containing particles of cyclosporin and a second part containing other components that can be combined with the first part to make a suspension formulation. The suspension can be injected into the subconjunctival or other periocular space to treat ocular conditions, such as dry eye disease.

Suspension compositions of cyclosporin A for subconjunctival and periocular injection

Ophthalmic products and related methods are described herein. These methods include a stabilizing composition comprising a therapeutically active agent which is separated from a liquid vehicle composition by a barrier. The barrier may be removed to allow the two compositions to mix to provide an ophthalmically acceptable liquid comprising the therapeutically active agent.

Two part formulation system for ophthalmic delivery

Stabilized ophthalmic compositions containing omega-3 oils are provided, which are useful as artificial tears and as ophthalmic compositions to diagnose, treat, or prevent keratoconjunctivitis or dry eye syndrome in a human or other mammal.

Stabilized omega-3 ophthalmic compositions

Disclosed herein are methods of formulating cyclosporin A Form 2.

Suspensions of cyclosporin A form 2

Compositions and methods related to ophthalmic use of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymers and therapeutic uses are described herein.

Ophthalmic compositions comprising polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymers

Androgen composition for treating an opthalmic condition

Growing community of inventors

Irvine, CA, United States of America

Anuradha V Gore